L-DOPA [59-92-7]
Cat# HY-N0304-1g
Size : 1g
Brand : MedChemExpress
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease.
For research use only. We do not sell to patients.
L-DOPA Chemical Structure
CAS No. : 59-92-7
This product is a controlled substance and not for sale in your territory.
Based on 14 publication(s) in Google Scholar
Other Forms of L-DOPA:
- L-DOPA-2,5,6-d3 In-stock
- L-DOPA-d6 In-stock
- L-DOPA-13C In-stock
- L-DOPA sodium Get quote
- L-DOPA-13C6 Get quote
Description |
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target |
|
||||||||||||||||
In Vivo |
L-DOPA can be used in animal modeling to construct a rat model of dyskinesia.
L-DOPA (20 mg/kg; oral) reduces Rotenone-induced motor dysfunction[3]. L-DOPA (10, 30, 50, 70, and 100 mg/kg; oral) reverses tactile, cold and heat allodynia in neuropathic rat without any side effect in sprague-Dawley rats[4].In adult common marmosets (Callithrix jacchus, 2-3 years old, 270-350 g), L-DOPA (20/5 mg/kg, p.o.) shows the Tmax was 30 min in plasma and 60-90 min in extracellular fluid (ECF) of striatum. Mean Cmax was 20.3 μM in plasma and 442.9 nM in ECF of striatum, which is about 2.2% of that in plasma[6]. Induction of dyskinesia model[5]
Background
L-DOPA-induced dyskinesia results from a pulsatile stimulation of brain dopamine (DA) receptors, triggering a complex cascade of molecular and synaptic alterations within the basal ganglia[5].
Specific Mmodeling Methods
Mice: C57Bl/6 mice?•?male?• 8 weeks (period: 21 days) Administration: 20 mg/kg?•?ip?•?once daily for 21 days
Note
(1) sustained unilateral 6-OHDA injections in the striatum before starting treatment.
(2) Injection volume is 10mL/kg body weight. Modeling Indicators
Behavioral changes: Shows developed abnormal involuntary movements (AIMs) affecting the head, trunk and forelimb on the side contralateral to the lesion.
Correlated Product(s): Oxidopamine hydrochloride (HY-B1081)
Opposite Product(s): Oxidopamine hydrobromide (HY-B1081A) MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
Molecular Weight |
197.19 |
||||||||||||||||
Formula |
C9H11NO4 |
||||||||||||||||
CAS No. |
59-92-7 |
||||||||||||||||
Appearance |
Solid |
||||||||||||||||
Color |
White to off-white |
||||||||||||||||
SMILES |
N[C@@H](CC1=CC(O)=C(C=C1)O)C(O)=O |
||||||||||||||||
Structure Classification |
|
||||||||||||||||
Initial Source |
|
||||||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
Storage |
4°C, stored under nitrogen *The compound is unstable in solutions, freshly prepared is recommended. |
||||||||||||||||
Solvent & Solubility |
In Vitro:
0.1 M HCL : 20 mg/mL (101.43 mM; ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C) H2O : 1 mg/mL (5.07 mM; Need ultrasonic) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended. * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
For the following dissolution methods, please prepare the working solution directly.
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration:
mg/mL
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
|
||||||||||||||||
Purity & Documentation |
Purity: 99.98% |
||||||||||||||||
References |
|
Complete Stock Solution Preparation Table
* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
H2O / 0.1 M HCL | 1 mM | 5.0713 mL | 25.3563 mL | 50.7125 mL | 126.7813 mL |
5 mM | 1.0143 mL | 5.0713 mL | 10.1425 mL | 25.3563 mL | |
0.1 M HCL | 10 mM | 0.5071 mL | 2.5356 mL | 5.0713 mL | 12.6781 mL |
15 mM | 0.3381 mL | 1.6904 mL | 3.3808 mL | 8.4521 mL | |
20 mM | 0.2536 mL | 1.2678 mL | 2.5356 mL | 6.3391 mL | |
25 mM | 0.2029 mL | 1.0143 mL | 2.0285 mL | 5.0713 mL | |
30 mM | 0.1690 mL | 0.8452 mL | 1.6904 mL | 4.2260 mL | |
40 mM | 0.1268 mL | 0.6339 mL | 1.2678 mL | 3.1695 mL | |
50 mM | 0.1014 mL | 0.5071 mL | 1.0143 mL | 2.5356 mL | |
60 mM | 0.0845 mL | 0.4226 mL | 0.8452 mL | 2.1130 mL | |
80 mM | 0.0634 mL | 0.3170 mL | 0.6339 mL | 1.5848 mL | |
100 mM | 0.0507 mL | 0.2536 mL | 0.5071 mL | 1.2678 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
L-DOPA Related Classifications
- Neuronal Signaling GPCR/G Protein Metabolic Enzyme/Protease
- Dopamine Receptor Endogenous Metabolite